Tollys

About:

Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor.

Website: http://tollys.fr/

Top Investors: Investisseurs privés

Description:

Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor. The company is advancing TL-532, a new cancer immunotherapy to treat various types of cancer. TL-532 is a structurally defined double-stranded RNA, produced synthetically and highly specific to the TLR3 receptor.

Total Funding Amount:

2.3M EUR

Headquarters Location:

Lyon, Rhone-Alpes, France

Founded Date:

2015-01-01

Contact Email:

contact(AT)tollys.fr

Founders:

Jacques-François Martin, Philippe Guillot-Chene

Number of Employees:

1-10

Last Funding Date:

2020-05-26

IPO Status:

Private

Industries:

© 2025 bioDAO.ai